SAS has secured a potential $49.9M blanket purchase agreement to provide the Food and Drug Administration access to the company’s cloud-based artificial intelligence, analytic and data management platform.
The FDA’s Center for Drug Evaluation and Research will implement the SAS Viya platform in efforts to update drug regulatory processes, monitor drug manufacturing facilities and support other public health initiatives, the company said Monday.
Jim Goodnight, SAS co-founder and CEO, said the company aims to help the FDA harness the power of new technology platforms to ensure the safety and accelerate the delivery of lifesaving medicines to people in the U.S.
The Cary, North Carolina-based software provider seeks to support ongoing digital transformation efforts at the agency through the BPA.
SAS noted that the Department of Health and Human Services uses company-made software across various programs such as enterprise performance management, disease surveillance and Medicare fraud detection.
